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Abstract
Background To better deﬁne the clinical signiﬁcance of
patient-reported outcomes, the concept of a minimum
clinically important difference (MCID) exists. The MCID
is the minimum change that a patient will perceive as
meaningful. Prior attempts to determine the MCID after
carpal tunnel release are limited by methodologic concerns,
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including the lack of a true anchor-based MCID
calculation.
Questions/purposes To address previous methodologic
concerns in existing studies, as well as establish a clinically
useful value for clinicians, we asked: What are the MCID
values for the Patient-Reported Outcomes Measurement
Information System (PROMIS) Upper Extremity (UE),
PROMIS Pain Interference (PI), and the QuickDASH after
carpal tunnel release?
Methods We conducted a prospective cohort study at an
urban, Midwest, multihospital, academic health system.
One hundred forty-seven adult patients undergoing unilateral carpal tunnel release between September 2020 and
February 2022 were identiﬁed. PROMIS UE, PI, and
QuickDASH scores were collected preoperatively and
3 months postoperatively. We also collected responses to
an anchor-based question: “Since your treatment, how
would you rate your overall function?” (much worse,
worse, slightly worse, no change, slightly improved, improved, or much improved). Patients who did not respond
to the 3-month postoperative surveys were excluded. A
total of 122 patients were included in the ﬁnal analysis
(83% response proportion [122 of 147]). The mean age was
57 years (range 23 to 87 years), and 68% were women. The
MCID was calculated using both anchor-based and
distribution-based methods. Although anchor-based calculations are generally considered more clinically relevant
because they consider patients’ perceptions of improvement, an estimation of the minimum detectable change
(which represents measurement error) relies on a
distribution-based calculation. We determined a range of
MCID values to propose a ﬁnal MCID value for all three
instruments. A negative MCID value for the PROMIS PI
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instrument represents a decrease in pain, whereas a positive
value for the PROMIS UE instrument represents an improvement in function. A negative value for the
QuickDASH instrument represents an increase in function.
Results The ﬁnal proposed MCID values were 6.2 (interquartile range [IQR] 5.4 to 9.0) for the PROMIS UE, -7.8
(IQR -6.1 to -8.5) for the PROMIS PI, and -18.2 (IQR -13.3
to -34.1) for the QuickDASH.
Conclusion We recommend that clinicians use the following values as the MCID after carpal tunnel release: 6 for
the UE, -8 for the PI, and -18 for the QuickDASH.
Surgeons may ﬁnd these values useful when counseling
patients postoperatively regarding improvement. Future
studies could examine whether a single MCID (or small
range) for PROMIS instruments is applicable to a variety of
conditions and interventions.
Level of Evidence Level II, therapeutic study.

Introduction
Recently, there has been an increasing emphasis on valuebased care in orthopaedics [41, 53]. To objectively measure
patients’ responses to treatment, patient-reported outcomes
(PROs) have been increasingly used [3, 37]. Two PRO instruments commonly used for patients with hand and upper
extremity illness are the QuickDASH [5] and the PatientReported Outcomes Measurement Information System
(PROMIS) [6, 9, 13, 51]. In contrast to the QuickDASH,
which is a ﬁxed-length questionnaire, PROMIS computer
adaptive testing uses item-response theory to minimize the
question burden and select the most appropriate questions in
response to a patient’s prior answers. The PROMIS has been
widely used in orthopaedic surgery and has been validated for
use in hand and upper extremity surgery [12, 37].
To better deﬁne the clinical importance of patients’
improvements in terms of PRO scores, the concept of the
minimum clinically important difference (MCID)
emerged. The MCID is the minimal change that a patient
will perceive as meaningful [29]. Although ﬁrst described
in 1989, there is still a lack of a standardized method to
calculate the MCID [16, 29, 31]. Current methods to estimate the MCID are anchor-based or distribution-based [14,
22]. Anchor-based calculations pair a PRO of interest to a
subjective scale of improvement or decline [17].
Distribution-based calculations are based on statistical
parameters unique to a particular cohort, such as the standard deviation (SD) or effect size [22, 39]. Because MCID
values for different PROs are being increasingly reported in
orthopaedic research, review articles have commented on
the wide variability in reported values, emphasizing the
need for clear reporting of the methods used [16, 31].
A key component in the evaluation of MCID calculations is the minimum detectable change (MDC) [4, 49].

The MDC is a measurement error that represents the
minimal change in a PRO that is not because of chance
alone [4]. For an MCID value to be valid, it should be
greater than the MDC value for the cohort of interest [49].
If the calculated MCID is less than the MDC value, the
PRO instrument may not be sufﬁciently responsive to detect the MCID [19, 24]. More importantly, patients expect
improvement from surgical intervention to be clinically
appreciable, not merely detectable in numbers. Therein lies
the entire concept of MCID.
Two previous studies have sought to calculate the
MCID for the PROMIS after carpal tunnel release (CTR)
[8, 33]. However, as highlighted in a commentary by
Terwee [48], these studies have several methodologic
limitations. Neither study calculated a true anchor-based
MCID value for the PROMIS, and instead relied on
distribution-based methods. Because distribution-based
methods do not consider the patient’s perspective, these
calculations often underestimate what is considered a
meaningful change to the patient [11, 22]. In addition, one
study did not report an MDC value, which the authors
recognized as a limitation and addressed as an important
next step in future research pertaining to the MCID [8]. The
second study reported MDC values that were greater than
their MCID values [33].
Therefore, we asked: What are the MCID values for the
PROMIS Upper Extremity (UE), PROMIS Pain
Interference (PI), and QuickDASH after CTR?

Patients and Methods
Study Design and Setting
We conducted a prospective cohort study at an urban,
Midwest, multihospital, academic health system.

Patients
A retrospective record review was performed to identify
patients who underwent open or endoscopic CTR, based
on Current Procedural Terminology codes for open and
endoscopic CTR (64721 and 29848), by four fellowshiptrained orthopaedic hand surgeons including the senior
author (CSD) between September 2020 and February
2022. Patients who underwent bilateral CTR (staged or
simultaneous), additional procedures at the time of CTR
(including injections), or revision CTR were excluded.
Patient demographics were recorded. At our institution,
patients undergoing CTR use a tablet to complete preoperative questionnaires, including the PROMIS UE
(version 2.0), PROMIS PI (version 1.1), and
QuickDASH. Patients’ responses are integrated into their
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Table 1. Responses to the anchor question “Since your
treatment, how would you rate your overall function?” (n = 122
responses)
Response to question: Since your
treatment, how would you rate your
overall function?
Much worse
Worse
Slightly worse
No change
Slightly improved
Improved
Much improved

3

worse [-1],” “no change [0],” and “slightly improved
[+1]”), and 33% (40 of 122) were included in the “improved” group (“improved [+2]”) (Table 1). There was
improvement in scores from preoperatively to postoperatively for all three PRO instruments (Table 2).

% (n)
1 (1)
1 (1)
4 (5)
2 (2)
20 (24)
33 (40)
40 (49)

electronic medical record. Patients who completed preoperative questionnaires were included in the study and
those who had incomplete preoperative questionnaires
were excluded. At 3 months postoperatively, patients who
met the inclusion criteria were prospectively sent questionnaires through the REDCap platform via an email that
contained these three PRO instruments [25]. To calculate
anchor-based MCIDs, patients were also asked to
answer a seven-level anchor question: “Since your treatment, how would you rate your overall function?” (much
worse [-3], worse [-2], slightly worse [-1], no change [0],
slightly improved [+1], improved [+2], and much improved [+3]).

Participants’ Baseline Data
A total of 147 unique patients met the inclusion criteria for
this study; 83% (122 of 147) responded to the 3-month
postoperative surveys. The mean age was 57 years (range
23 to 87 years), and 68% (83 of 122) were women. Fortythree percent of patients (52 of 122) underwent open CTR,
and 57% (70 of 122) underwent endoscopic CTR. PRO
instruments were completed at a mean 1.3 6 1.2 months
preoperatively. The mean time from surgery to completion
of the postoperative survey was 4.1 6 0.98 months.
Twenty-six percent (31 of 122 patients) of the cohort
were included in the “nonimproved” group (“slightly

Survey Instruments
PROMIS instruments were administered using computer
adaptive testing [46]. The scores in PROMIS measures are
computed to a T-score where a score of 50 represents the
average level of the instrument for the United States general population and 10 is the SD.
The PROMIS UE (version 2.0) assesses upper extremity
physical function in patients [51]. A lower score represents
decreased function, and a higher score represents better
function. The PROMIS PI (version 1.1) assesses pain severity [2]. A higher score represents increased pain levels
while a lower score represents decreased pain.
The QuickDASH is an outcome measure that also attempts to quantify upper extremity function [5]. It is scored
on a scale of 0 to 100, with 0 representing no dysfunction
and 100 representing maximum dysfunction.

Analytic Approach
The MCID was calculated using both anchor-based and
distribution-based methods. Although anchor-based calculations are generally considered more clinically relevant
because they consider patients’ perceptions of improvement, an estimation of the MDC (which represents measurement error) relies on a distribution-based calculation.
Descriptive statistics were calculated (mean, median,
range, and SD). Ninety-ﬁve percent conﬁdence intervals
were calculated using the mean 6 2*SD. Normality of
continuous variables was assessed using the Shapiro-Wilk
test. Preoperative and postoperative scores were compared
using two-tailed paired t-tests for normal distributions and
the Wilcoxon rank sum test for non-normal distributions.
Statistical signiﬁcance was set at a p value of < 0.05. All
statistical analyses were performed with JMP® (Version
16.2.0, SAS Institute Inc).

Table 2. Preoperative, postoperative, and diﬀerence in scores for the PROMIS UE, PROMIS PI, and QuickDASH
Questionnaire

Preoperative score, mean 6 SD

Postoperative score, mean 6 SD

Mean diﬀerence (95% CI)

p value

36.3 6 7.9
59.4 6 7.0
45.7 6 17.6

46.1 6 11.3
49.4 6 9.8
18.1 6 21.1

9.8 (8.1 to 11.7)
-10.0 (-8.2 to -11.8)
-27.6 (23.7 to 31.5)

< 0.01a
< 0.01b
< 0.01b

PROMIS UE
PROMIS PI
QuickDASH
a

Wilcoxon rank sum test
Student paired t-test.

b
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Table 3. PROMIS UE MCID estimates (n = 122)
Type
Anchor-based
Anchor-based
Anchor-based
Anchor-based
Distribution-based
Distribution-based
Distribution-based

Method

Calculated MCID value

% of patients meeting the MCID
threshold (n)

Mean change diﬀerence
Median change diﬀerence
Mean change limit
ROC curve
0.5*SD
0.8*SD
MDC95

6.7
6.2
18.3
5.4
5.7
9
2.2

55 (67)
57 (70)
22 (27)
62 (76)
60 (73)
48 (59)
75 (91)

Sample Size Calculation

Currently, there is no consensus on what constitutes a
sufﬁcient sample size for an accurate calculation of the
MCID [16]. However, we performed an a priori sample
size calculation to detect a 5-point change in PROMIS UE
and PI scores with a previously established SD of 10 (effect
size of 0.5) [43] and setting power to 80% and a = 0.05. We
determined that approximately 25 patients in each group
(baseline group reporting no improvement and a second
group reporting improvement) were required. We also
referenced two previous studies calculating the MCID for
the PROMIS after CTR [8, 33] and decided to include a
minimum of 100 patients in our total population.

Using Both Distribution-based and Anchor-based Methods

Although anchor-based calculations are generally considered more clinically relevant because they consider patients’ perceptions of improvement [35], distribution-based
methods still have utility. For example, an estimation of the
MDC, a surrogate for the measurement error of a PRO,
relies on a distribution-based calculation. Furthermore,
there is general consensus that there is no gold standard for
calculating an MCID and that both methods should be
considered together to calculate a single value or a small

range of MCID values [42, 54]. For these reasons, we used
both distribution-based and anchor-based methods in our
study.

Distribution-based Calculation Methods

Using the well-established 0.5 SD method, we calculated
the MCID as one-half times the SD of the measured change
in PRO scores [16, 39]. This is based on the ﬁnding that
most health-related quality of life instruments have an effect size of roughly 0.495 [39]. We also performed a post
hoc calculation of effect size between preoperative and
postoperative scores after collecting data, and a large effect
size was noted for all three PRO instruments (Cohen d >
0.8). A large effect size may represent a larger numerical
change in the instrument used (rather than simply a large
improvement), and thus a 0.8 times SD calculation was also
performed to estimate the MCID as originally recommended by Cohen [15, 32, 39, 44].
We also estimated the lowest possible MCID using the
MDC. We calculated the MDC95 (95% level of conﬁdence)
using established formulas (Supplemental Digital Content
1; http://links.lww.com/CORR/A958) [16, 45]. We
obtained Cronbach alpha or r values representing the testretest reliability coefﬁcient of all three PRO instruments
from previous studies speciﬁcally calculating these values

Table 4. PROMIS PI MCID estimates (n = 122)
Type
Anchor-based
Anchor-based
Anchor-based
Anchor-based
Distribution-based
Distribution-based
Distribution-based

Method

Calculated MCID value

% of patients meeting the MCID
threshold (n)

Mean change diﬀerence
Median change diﬀerence
Mean change limit
ROC curve
0.5*SD
0.8*SD
MDC95

-7.8
-8.5
-17.3
-7.1
-5.1
-8.1
-6.1

58 (71)
53 (65)
27 (33)
62 (76)
67 (82)
58 (71)
64 (78)
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Table 5. QuickDASH MCID estimates (n = 122)
Type
Anchor-based
Anchor-based
Anchor-based
Anchor-based
Distribution-based
Distribution-based
Distribution-based

Method

Calculated MCID value

% of patients meeting the MCID
threshold (n)

Mean change diﬀerence
Median change diﬀerence
Mean change limit
ROC curve
0.5*SD
0.8*SD
MDC95

-22.3
-18.2
-51.1
-34.1
-10.3
-16.4
-13.3

61 (74)
73 (89)
14 (17)
41 (50)
79 (96)
73 (89)
77 (94)

(UE = 0.99 [51]; PI = 0.90 [10]; QuickDASH = 0.94 [40]),
rather than calculating this value from our own dataset to
avoid bias, because patients in our study underwent an
intervention.

Anchor-based Calculation Methods

To calculate the MCID using anchor-based methods, we
preemptively designated patients who reported “improvement” (+2) on the seven-level anchor question as the
improved group (anchor) and patients who reported
“slightly worse” (-1), “no change” (0), or “slight improvement” (+1) as the nonimproved (base) group [26].
Patients seldom responded with “no change” postoperatively in a previous study attempting to calculate the
MCID after CTR [33] and in a study calculating the MCID
after shoulder arthroplasty [26]. Because CTR has an extremely high rate of postoperative satisfaction among patients (mean of 8 on a 10-point Lickert scale) [36], we
anticipated that designating “slightly improved” (+1) and
“no change” (0) as the two groups would yield minimum
sample sizes.
The mean change difference, median change difference,
and mean change limit methods were used to calculate the
MCID (Supplemental Digital Content 2; http://links.lww.
com/CORR/A959) [16]. We also calculated the MCID
using receiver operating characteristic curves to determine
an optimal cutoff score in the anchor and base groups (by
maximizing sensitivity and speciﬁcity using Youden
index [55]).

Proposed Final MCID Values

For the seven different MCID values calculated for each PRO
instrument, we determined whether the distribution of values
exhibited a normal or skewed distribution. For all three
instruments, a positively skewed distribution of MCID values
was present. We calculated the median MCID value as well as
the interquartile range (IQR) of the combined anchor-based
and distribution-based estimates. Because of the skewed
distribution, we report the median as the measure of central
tendency and use the IQR to represent error (rather than the
mean with a conﬁdence interval for a normal distribution).

Ethical Approval
This study was approved by the institutional review board
at our institution (number 11361-29).

Results
Anchor-based and distribution-based calculation methods
yielded a wide range of MCID estimates for the PROMIS
UE (Table 3), PROMIS PI (Table 4), and QuickDASH
(Table 5). Our ﬁnal proposed MCID values are as follows:
PROMIS UE = 6.2 (IQR 5.4 to 9.0), PROMIS PI = -7.8
(IQR -6.1 to -8.5), and QuickDASH = -18.2 (IQR -13.3 to
-34.1) (Table 6). A negative MCID value for the PROMIS
PI instrument represents a decrease in pain, whereas a
positive value for the PROMIS UE instrument represents

Table 6. Proposed MCID values for the PROMIS UE, PROMIS PI, and QuickDASH (n = 122)
Instrument

Median MCID (proposed) (IQR)

% of patient population meeting
median MCID (n)

PROMIS UE
PROMIS PI
QuickDASH

6.2 (5.4 to 9.0)
-7.8 (-6.1 to -8.5)
-18.2 (-13.3 to -34.1)

57 (69)
63 (77)
67 (82)

A positive value for the PROMIS UE instrument represents an improvement in function. A negative MCID value for the PROMIS PI
instrument represents a decrease in pain. A negative value for the QuickDASH instrument represents an increase in function.
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an improvement in function. A negative value for the
QuickDASH instrument represents an increase in function.

Discussion
The MCID revolves around that the idea that patients undergoing an intervention expect improvement to be clinically appreciable, not merely detectable by statistical
means [35]. In this study, we comprehensively calculated
MCID values for the PROMIS UE, PROMIS PI, and
QuickDASH PRO instruments after CTR using anchorbased and distribution-based methods. We sought to address the methodologic concerns in existing studies and
establish clinically useful values for clinicians. The MCID
values for CTR in our study (PROMIS UE 6.6, PROMIS PI
-7.0, and QuickDASH -15.3) were slightly larger than
those reported (PROMIS UE 3.6 to 4.2, PROMIS PI -3.4 to
-4.1, and QuickDASH -10.4) [8, 33].

Limitations
There are several limitations to our study. The ideal study for
calculating MCID using anchor-based methods would use
patients who responded “slightly improved” (+1) and “no
change” (0) to the anchor question. This was not possible in
our study owing to the very small number of patients falling
into the “no change” category, given the overall high rate of
satisfaction after CTR [36]. Therefore, we designated the
“improved (+2)” response as the improved group and the
combination of -1, 0, and 1 responses as the nonimproved
groups, possibly resulting in a slight overestimation of the
MCID. However, this method has been reported by other
studies with similar limitations imposed by the condition or
intervention itself during MCID calculation [26, 29].
Second, we did not exclude patients who experienced a
ceiling effect, particularly for the PROMIS UE instrument,
which may have also resulted in a slight underestimation of
the MCID. Tyser et al. [51] demonstrated improved ceiling
effects of the PROMIS UE version 2.0 (approximately 6.9%
at a value of 61) compared with prior versions of the UE
instrument. In our population, 2.5% (three of 122) of patients
who fell into our two anchor classiﬁcations of “nonimproved” and “improved” met this ceiling effect preoperatively and 5% (six of 122) met this ceiling effect
postoperatively. Because of the low percentage of patients
meeting the ceiling effect in our population, we believe the
effect on the MCID calculation was minimal.
The MCID values we calculated are the most applicable
to patients who are demographically similar to those in our
study. Other patient populations with racial, cultural, or
demographic differences from our cohort may respond to
the anchor question and PRO questionnaires differently.

However, given our large sample size, more than 80%
follow-up, and vigorous calculation methods, we believe
our MCID values are accurate and can be conﬁdently used
in future studies. Our study was also underpowered to
perform a subgroup analysis on whether men and women
have different MCIDs after CTR. Therefore, our results are
the most applicable to a population with a similar gender
distribution to ours (68% women).
Another general limitation of MCID calculations that is
applicable to our study is that the exact follow-up time
period in which to readminister the PRO instruments has
not been established. The responsiveness of PROMIS in
the early postoperative period after CTR has been questioned by a recent study that showed that at 1 month after
CTR, patients who reported subjective improvement had
PROMIS scores reﬂecting declining function [7]. We also
observed this phenomenon in our early postoperative data
(not reported). However, patient improvement has been
reported to peak at 6 months after CTR [23]. On the other
hand, longer follow-up periods may portend a higher risk
of anchoring bias and recall bias because anchor-based
MCID calculations depend on patients recalling their preoperative state [21, 30, 50]. To avoid potential bias because
of a too-early or too-late follow-up interval, we selected a
3-month follow-up period, which appears to be an appropriate time period to mitigate the effects of recall bias on
anchor-based MCID calculations [1, 38].

MCID Values
In our study, the MCID values for PROMIS UE, PROMIS
PI, and QuickDASH after CTR were greater than previously
reported [8, 33]. Our ﬁndings suggest that a greater increase
in function (PROMIS UE and QuickDASH) and a greater
decrease in pain (PROMIS PI) than reported represents a
“minimally” important change to a patient after this extremely prevalent surgery. One self-reported limitation of
the two previous studies calculating MCID after CTR is that
neither used a true anchor-based method. Several studies
have reported that anchor-based and distribution-based
methods can yield substantially different values [14, 16,
28]. Because distribution-based methods do not consider
patient-reported change, these calculations may not accurately represent the clinical importance of the change, which
is perhaps why our study resulted in larger MCID values [11,
16, 45, 52]. We addressed this limitation by incorporating
anchor-based methods and modiﬁed distribution-based
methods (considering the effect size of the change in
score) in our MCID calculations. Although anchor-based
MCID derivations tend to be viewed more favorably than
distribution-based calculations, there is no universal standardized method of calculating the MCID. Therefore, we felt
it was prudent to include both approaches, which allows
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for a comparison of distribution-based MCID values with
values in previous studies.
We also demonstrated the MDC95 was less than our
proposed MCID value for the PROMIS UE, PROMIS PI,
and QuickDASH, suggesting that our MCID values
represent a clinically important change that is not simply
because of random variation. If the MCID is smaller than
the MDC, the measured change could be due to random
chance [16, 18, 20]. Kazmers et al. [33] reported an MCID
for the UE and PI instruments that was lower than their
reported MDC, which suggests that their MCID may be too
low. We believe this difference is likely because of the way
the MDC was calculated. The MDC should be calculated
with a standard error of measurement using Cronbach alpha (r value, test-retest probability) of the actual instrument
rather than an r value calculated based on the change the
study is measuring, because this introduces bias [11, 48].
Although there is almost universal agreement that the
MDC should be factored into any calculation of the MCID,
many studies on the MCID have not reported this [16, 20].
For future studies, we recommend reporting the MDC of
the instrument alongside the actual MCID value to ensure
that the calculated MCID is free from measurement error.
Previous studies have attempted to evaluate the MCID
value of PROMIS instruments speciﬁc to a single condition
using anchor-based approaches. Kazmers et al. [34] proposed an MCID of 4.2 to 4.8 for the PROMIS UE instrument after ligament reconstruction and tendon
interposition for basilar thumb arthritis, and Hollenberg
and Hammert [27] found an MCID of 6.8 for the PI after
operative treatment of distal radius fractures. Overall, these
values are similar to the values we proposed as the MCID
after CTR in this study. Our ﬁndings, together with previous studies, suggest that a universal MCID value may be
applicable to each PRO instrument rather than speciﬁc to a
single pathologic condition. However, in the clinical setting, it is reasonable to hypothesize that the minimal improvement after treatment for trigger ﬁnger would be
different than after a total elbow replacement. We believe
MCID estimates depend on the pathology, intervention,
and population, as has been shown before [47].

Conclusion
We suggest the following MCIDs after CTR: PROMIS UE
6, PROMIS PI -8, and QuickDASH -18. Surgeons could
ﬁnd these values useful when counseling patients postoperatively regarding their improvement. We believe these
values represent a true improvement patients will recognize
as a small but meaningful change. Our study also highlights
that anchor-based and distribution-based MCID calculations
can yield different values. Currently, there is not a universal
consensus on whether one approach is the gold standard.
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Future studies should investigate the true differences between these different methods using multiple evaluations
and determine whether one is truly superior to the other. In
addition, future studies could examine whether a single
MCID (or small range) for PROMIS instruments can be
applicable to a variety of conditions and interventions.
Acknowledgments We thank Eric C. Makhni MD, MBA for leading
the integration of the PROMIS instrument into Henry Ford Health System.
We also thank Yueren Zhou PhD for her statistical expertise.
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